Home Cytoskeletal Signaling -Cell Cycle PAK

PAK Inhibitors

Isoform-selective Products

PAK Products

  • All (15)
  • PAK Inhibitors (12)
  • New PAK Products
Cat.No. Product Name Information Product Use Citations Product Validations
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Sci Adv, 2025, 11(31):eadu4270
Sci Rep, 2024, 14(1):7739
J Exp Med, 2023, 220(9)e20230054
Verified customer review of PRT062607 (P505-15) HCl
S7093 IPA-3 IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).
Discov Oncol, 2025, 16(1):364
Nat Commun, 2024, 15(1):2989
Biomolecules, 2024, 14(2)237
Verified customer review of IPA-3
S7271 FRAX597 FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
BMC Biol, 2025, 23(1):166
J Cell Physiol, 2024, 10.1002/jcp.31291
Sci Rep, 2024, 14(1):4060
Verified customer review of FRAX597
S7094 PF-3758309 PF-03758309 (PF-03758309) is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with Kd of 2.7 nM. This compound is antiproliferative and induces apoptosis in a HCT116 tumor model.
Cell Commun Signal, 2025, 23(1):135
Nat Commun, 2024, 15(1):3178
Oncogene, 2023, 42(39):2878-2891
Verified customer review of PF-3758309
S7807 FRAX486 FRAX486 is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively.
iScience, 2023, 26(8):107333
Biochim Biophys Acta Mol Cell Res, 2022, 1869(8):119264
J Mol Cell Biol, 2021, 13(1):41-58
S8444 Padnarsertib (KPT 9274) Padnarsertib (KPT 9274) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.
Signal Transduct Target Ther, 2025, 10(1):222
Cell Rep Med, 2024, 5(2):101416
Sci Rep, 2023, 13(1):3334
S7989 FRAX1036 FRAX-1036 is a potent and selective PAK inhibitor with biochemical potency (Ki) of 23.3 nM and 72.4 nM against PAK1 and PAK2.
bioRxiv, 2023, 10.1101/2023.12.15.571909
Cell Rep, 2022, 41(1):111442
Nature, 2021, 595(7869):730-734
S8264 NVS-PAK1-1 NVS-PAK1-1 is a potent and selective allosteric p21-activated kinase 1 (PAK1) inhibitor with an IC50 of 5 nM.
NPJ Breast Cancer, 2023, 9(1):48
J Med Chem, 2022, 65(23):15627-15641
S1976 LCH-7749944 LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has less potently inhibitory effect against PAK1, PAK5 and PAK6. This compound causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4.
J Exp Clin Cancer Res, 2025, 44(1):134
Endocrinology, 2023, 164(6)bqad073
F1046 PAK2 Antibody [N15H3] Serine/threonine-protein kinase PAK 2, Gamma-PAK, PAK65, S6/H4 kinase, p21-activated kinase 2 , PAK-2, p58, PAK2, Serine/threonine-protein kinase PAK 3, Beta-PAK Oligophrenin-3, p21-activated kinase 3, PAK-3, PAK3, OPHN3, Serine/threonine-protein kinase PAK 1, Alpha-PAK,α-PAK, p21-activated kinase 1, PAK-1, p65-PAK
F2117 Phospho-PAK1/2/3 (Ser144/141/154) Antibody [A5J4]
E2484 Hydrastine Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine), a natural alkaloid present in Hydrastis canadensis, is an inhibitor of PAK4.
F3217New PAK1 Antibody [P10N18]
S8139New G-5555 G-5555 is a selective inhibitor of Group I p21-activated kinases (PAKs), including PAK1, PAK2, and PAK3, with Ki values of 3.7 nM for PAK1 and 11 nM for PAK2.
E2380 GNE 2861 GNE 2861, a PAK inhibitor that displays group II selectivity, inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
S8032 PRT062607 (P505-15) HCl PRT062607 (P505-15, BIIB057, PRT-2607) HCl is a novel, highly selective Syk inhibitor with IC50 of 1 nM in cell-free assays, >80-fold selective for Syk than Fgr, PAK5, Lyn, FAK, Pyk2, FLT3, MLK1 and Zap70.
Sci Adv, 2025, 11(31):eadu4270
Sci Rep, 2024, 14(1):7739
J Exp Med, 2023, 220(9)e20230054
 Verified customer review of PRT062607 (P505-15) HCl
S7093 IPA-3 IPA-3 is a selective non-ATP competitive Pak1 inhibitor with IC50 of 2.5 μM in a cell-free assay, no inhibition to group II PAKs (PAKs 4-6).
Discov Oncol, 2025, 16(1):364
Nat Commun, 2024, 15(1):2989
Biomolecules, 2024, 14(2)237
 Verified customer review of IPA-3
S7271 FRAX597 FRAX597 is a potent, ATP-competitive inhibitor of group I PAKs with IC50 of 8 nM, 13 nM, and 19 nM for PAK1, PAK2, and PAK3, respectively.
BMC Biol, 2025, 23(1):166
J Cell Physiol, 2024, 10.1002/jcp.31291
Sci Rep, 2024, 14(1):4060
 Verified customer review of FRAX597
S7094 PF-3758309 PF-03758309 (PF-03758309) is a potent, ATP-competitive, pyrrolopyrazole inhibitor of PAK4 with Kd of 2.7 nM. This compound is antiproliferative and induces apoptosis in a HCT116 tumor model.
Cell Commun Signal, 2025, 23(1):135
Nat Commun, 2024, 15(1):3178
Oncogene, 2023, 42(39):2878-2891
 Verified customer review of PF-3758309
S7807 FRAX486 FRAX486 is a potent p21-activated kinase (PAK) inhibitor with IC50 values of 14, 33, 39 and 575 nM for PAK1, PAK2, PAK3 and PAK4 respectively.
iScience, 2023, 26(8):107333
Biochim Biophys Acta Mol Cell Res, 2022, 1869(8):119264
J Mol Cell Biol, 2021, 13(1):41-58
S8444 Padnarsertib (KPT 9274) Padnarsertib (KPT 9274) is an orally bioavailable small molecule that is a non-competitive dual inhibitor of PAK4 and NAMPT. It shows an IC50 of ~120 nM for NAMPT in a cell-free enzymatic assay.
Signal Transduct Target Ther, 2025, 10(1):222
Cell Rep Med, 2024, 5(2):101416
Sci Rep, 2023, 13(1):3334
S7989 FRAX1036 FRAX-1036 is a potent and selective PAK inhibitor with biochemical potency (Ki) of 23.3 nM and 72.4 nM against PAK1 and PAK2.
bioRxiv, 2023, 10.1101/2023.12.15.571909
Cell Rep, 2022, 41(1):111442
Nature, 2021, 595(7869):730-734
S8264 NVS-PAK1-1 NVS-PAK1-1 is a potent and selective allosteric p21-activated kinase 1 (PAK1) inhibitor with an IC50 of 5 nM.
NPJ Breast Cancer, 2023, 9(1):48
J Med Chem, 2022, 65(23):15627-15641
S1976 LCH-7749944 LCH-7749944 (GNF-PF-2356) is a novel and potent p21-activated kinase 4 (PAK4) inhibitor with an IC50 of 14.93 μM and has less potently inhibitory effect against PAK1, PAK5 and PAK6. This compound causes successful inhibition of EGFR activity due to its inhibitory effect on PAK4.
J Exp Clin Cancer Res, 2025, 44(1):134
Endocrinology, 2023, 164(6)bqad073
E2484 Hydrastine Hydrastine ((-)-β-Hydrastine; (1R,9S)-β-Hydrastine), a natural alkaloid present in Hydrastis canadensis, is an inhibitor of PAK4.
S8139New G-5555 G-5555 is a selective inhibitor of Group I p21-activated kinases (PAKs), including PAK1, PAK2, and PAK3, with Ki values of 3.7 nM for PAK1 and 11 nM for PAK2.
E2380 GNE 2861 GNE 2861, a PAK inhibitor that displays group II selectivity, inhibits PAK4, PAK5 and PAK6 with IC50s of 7.5, 36, 126 nM, respectively.
F3217New PAK1 Antibody [P10N18]
S8139New G-5555 G-5555 is a selective inhibitor of Group I p21-activated kinases (PAKs), including PAK1, PAK2, and PAK3, with Ki values of 3.7 nM for PAK1 and 11 nM for PAK2.

Signaling Pathway Map